PE shop boys
13 April 2020

The private-equity firm is sinking $2 bln into Alnylam, including buying rights to future revenue from a drug still under regulatory review. It’s a way to match Blackstone’s bulging wallet with the biotech’s hefty costs while limiting exposure to volatile equity markets.